Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1

Malta - English - Malta Medicines Authority

astrazeneca ab se-151 85, södertälje, sweden - goserelin - implant - goserelin 3.6 mg - endocrine therapy

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - goserelin/(lhrh analogue) -

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - goserelin - implant - 10.8 milligram(s) - gonadotropin releasing hormone analogues; goserelin

Ireland - English - HPRA (Health Products Regulatory Authority)

profind wholesale ltd - goserelin acetate - implant - 10.8 base milligrams

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer, where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m plus) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, astrazeneca goserelin shrinks the lesions and reduces the symptoms, including pain. astrazeneca goserelin also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce operativeblood loss. endometrial thinning: use as an endometrial thinning agent prior to endometrial ablation. assisted reproduction: pituitary down regulation in preparation for controlled ovarian superstimulation.

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca ab - goserelin - implant - 3.6 milligram(s) - gonadotropin releasing hormone analogues; goserelin

Australia - English - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - ulipristal acetate -

Namibia - English - Namibia Medicines Regulatory Council

astrazeneca pharmaceuticals (pty) ltd - goserelin acetate - injection - each zoladex depot contains goserelin acetate equiv. to goserelin base 10,8 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 10.8 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer , where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.